Brief Article
Copyright ©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Jun 7, 2012; 18(21): 2661-2667
Published online Jun 7, 2012. doi: 10.3748/wjg.v18.i21.2661
Table 1 General characteristics of the study population n (%)
Totaln = 2242FHx (-)n = 2077 (92.6%)FHx (+)n = 165 (7.4%)P value
GenderMale1765 (78.7)1639 (78.9)126 (76.4)0.441
Female477 (21.3)438 (21.1)39 (23.6)
AgeMedian (min-max)57.0 (18.0-89.0)57.0 (18.0-89.0)52.0 (29.0-79.0)< 0.0001
< 201 (0.1)1 (0.1)0 (0.0)< 0.001
20-2913 (0.5)12 (0.6)1 (0.6)
30-39112 (5.0)99 (4.8)13 (7.9)
40-49458 (20.4)410 (19.7)48 (29.1)
50-59722 (32.2)661 (31.8)61 (37.0)
60-69640 (28.6)606 (29.2)34 (20.6)
70-79256 (11.4)248 (11.9)8 (4.8)
≥ 8040 (1.8)40 (1.9)0 (0.0)
EtiologyHBV1683 (75.1)1548 (74.5)135 (81.8)0.236
HCV296 (13.2)280 (13.5)16 (9.6)
Alcohol70 (3.1)68 (3.3)2 (1.2)
Combined32 (1.4)31 (1.5)1 (0.6)
Others50 (2.2)45 (2.2)5 (3.0)
Unknown111 (5.0)105 (5.0)6 (3.6)
HBVHBV (+)1713 (76.4)1577 (75.9)136 (82.4)0.058
HBV (-)529 (23.6)500 (24.1)29 (17.6)
HCVHCV (+)315 (14.1)298 (14.3)17 (10.3)0.15
HCV (-)1927 (85.9)1779 (86.7)148 (89.6)
StageI185 (8.3)167 (8.0)18 (10.9)0.221
II655 (29.2)602 (29.0)54 (32.7)
III648 (28.9)610 (29.4)38 (23.1)
IVa and IVb753 (33.6)698 (33.6)55 (33.3)
Lab,ALT (U/L)47.0 (3.0-3505.0)47.0 (3.0-3505.0)47.5 (3.0-840.0)0.987
median (min-max)TB (mg/mL)1.1 (0.1-47.6)1.1 (0.1-47.6)1 (0.1-26.0)0.868
Alb (g/dL)3.5 (1.2-9.6)3.5 (1.2-9.6)3.7 (1.6-5.0)0.106
Platelet (x 103/μL)121.5 (8.0-1084.0)121.0 (18.0-1084.0)133.0 (8.0-635.0)0.181
Tumor markers,AFP (ng/ mL)69.1 (0.0-529 470.0)67.00 (0.0-529 470.0)110.8 (1.1-53 606.0)0.972
median (min-max)PIVKA-II (Mau/mL)88.0 (1.0-16 636.8)92.0 (1.0-16 636.8)80.0 (6.0-2000.0)0.990
Table 2 Distribution of patients with positive family history by age and tumor staging n (%)
nAge (yr, median)RangeP value
Family members
Father295329.0-78.00.101
Mother4248.533.0-79.0
Siblings1023930.0-48.0
HBV infectionHBV (+) (n = 136)HBV (-) (n = 29)
AgeMedian (min-max)52.0 (30.0-78.0)57.0 (29.0-79.0)0.065
< 200 (0.0)0 (0.0)0.001
20-290 (0.0)1 (3.4)
30-3912 (8.8)1 (3.4)
40-4939 (28.7)9 (31.0)
50-5956 (41.2)5 (17.5)
60-6926 (19.1)8 (27.6)
70-793 (2.2)5 (17.2)
≥ 800 (0.0)0 (0.0)
Stage117 (12.5)1 (3.4)0.056
246 (33.8)8 (27.6)
326 (19.1)12 (41.4)
447 (33.6)8 (27.6)
HCV infectionHCV (+) (n = 18)HCV (-) (n = 147)
AgeMedian (min-max)54.0 (29.0-75.0)52.0 (30.0-79.0)0.629
< 200 (0.0)0 (0.0)0.026
20-291 (5.9)0 (0.0)
30-391 (5.9)12 (8.1)
40-495 (29.4)43 (29.1)
50-593 (17.6)58 (39.2)
60-696 (35.3)28 (18.9)
70-791 (5.9)7 (4.7)
≥ 800 (0.0)0 (0.0)
Stage118 (12.2)0 (0.0)0.335
249 (33.1)5 (29.4)
332 (21.6)6 (35.3)
449 (33.1)6 (35.3)
Table 3 Characteristics of study subjects based on hepatitis B virus infection and family history n (%)
HBV (+) (n = 1713)
P valueHBV (-) (n = 529)
P value
FHx (+) (n = 136)FHx (-) (n = 1577)FHx (+) (n = 29)FHx (-) (n = 500)
Age, median (range)52 (30.0-78.0)57 (18.0-89.0)< 0.000157 (29.0-79.0)61 (22.0-88.0)0.164
Age group< 4526 (19.1)197 (12.5)0.0285570.244
≥ 45110 (80.9)1380 (87.5)24443
Stage117 (12.5)122 (7.7)0.0181 (2.2)45 (9.0)0.364
246 (33.8)443 (28.1)8 (27.6)159 (31.8)
326 (19.1)473 (30.0)12 (41.4)137 (27.4)
447 (34.6)539 (34.2)8 (27.6)159 (31.8)
non-HBVHCV16 (55.2)280 (56.0)0.481
Alcohol2 (6.9)68 (13.6)
Combined0 (0.0)2 (0.4)
Others5 (17.2)45 (9.0)
Unknown6 (20.7)105 (21.0)